Whats a fair price for remdesivir? How do we know whether vaccines work? And does AI have a place in end-of-life care?<\/p>\n
We discuss all that and more this week on The Readout LOUD, STATs biotech podcast. First, we dig into the long-awaited price for Gilead Sciences Covid-19 treatment and break down the disparate reactions from lawmakers, activists, and Wall Street analysts. Then, STATs Matthew Herper joins us to discuss some of the first detailed data on a potential vaccine for the novel coronavirus. Finally, we talk about a new use for AI: nudging clinicians to broach delicate conversations with patients about their end-of-life goals and wishes.<\/p>\n
For more on what we cover, heres the remdesivir news; heres more on the vaccine data; heres the story on AI; and heres the latest in STATs coronavirus coverage.<\/p>\n
advertisement<\/p>\n
Well be back next Thursday evening and every Thursday evening so be sure to sign up onApple Podcasts,Stitcher,Google Play, or wherever you get your podcasts.<\/p>\n
And if you have any feedback for us topics to cover, guests to invite, vocal tics to cease you can emailreadoutloud@statnews.com<\/a>.<\/p>\n advertisement<\/p>\n Interested in sponsoring a future episode of The Readout LOUD? Email us atmarketing@statnews.com<\/a>.<\/p>\n <\/p>\n Read more from the original source: <\/p>\n Remdesivir's controversial cost, early vaccine data, and AI at the end of life - STAT<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Whats a fair price for remdesivir? How do we know whether vaccines work? And does AI have a place in end-of-life care Continue reading